Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…Abstract Number: 0272 • ACR Convergence 2023
Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…Abstract Number: 0855 • ACR Convergence 2023
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…Abstract Number: 1871 • ACR Convergence 2023
Utility of Infrared Thermography in Patients with Digital Gangrene
Background/Purpose: Digital gangrene has been described as a complication of several Autoimmune Inflammatory Rheumatic Diseases(AIIRD). Due to multiple underlying mechanisms causing digital gangrene in AIIRD…Abstract Number: 2397 • ACR Convergence 2023
Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis
Background/Purpose: Environmental air pollution (AP) has been found to affect vascular inflammation and to contribute to the risk of onset and flare of autoimmune diseases1,2.…Abstract Number: 2420 • ACR Convergence 2023
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in North America and Western Europe. GCA is more likely to occur in women (1).…Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…Abstract Number: 0703 • ACR Convergence 2023
Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…Abstract Number: 1552 • ACR Convergence 2023
Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) belongs to the group of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). There are no recent data on…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 35
- Next Page »